TR199900155T2 - Bir IgE ba�lama alan� ve bir HSA bile�eni ihtiva eden f�zyon polipeptidleri, ve onlar�n te�hise ve tedaviye ait kullan�mlar�. - Google Patents

Bir IgE ba�lama alan� ve bir HSA bile�eni ihtiva eden f�zyon polipeptidleri, ve onlar�n te�hise ve tedaviye ait kullan�mlar�.

Info

Publication number
TR199900155T2
TR199900155T2 TR1999/00155T TR9900155T TR199900155T2 TR 199900155 T2 TR199900155 T2 TR 199900155T2 TR 1999/00155 T TR1999/00155 T TR 1999/00155T TR 9900155 T TR9900155 T TR 9900155T TR 199900155 T2 TR199900155 T2 TR 199900155T2
Authority
TR
Turkey
Prior art keywords
fusion polypeptides
ige
diagnostic
binding domain
polypeptides containing
Prior art date
Application number
TR1999/00155T
Other languages
English (en)
Turkish (tr)
Inventor
Ellen Digan Mary
Lake Philip
Gram Hermann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TR199900155T2 publication Critical patent/TR199900155T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TR1999/00155T 1996-07-26 1997-07-25 Bir IgE ba�lama alan� ve bir HSA bile�eni ihtiva eden f�zyon polipeptidleri, ve onlar�n te�hise ve tedaviye ait kullan�mlar�. TR199900155T2 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69021696A 1996-07-26 1996-07-26

Publications (1)

Publication Number Publication Date
TR199900155T2 true TR199900155T2 (xx) 2000-08-21

Family

ID=24771594

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/00155T TR199900155T2 (xx) 1996-07-26 1997-07-25 Bir IgE ba�lama alan� ve bir HSA bile�eni ihtiva eden f�zyon polipeptidleri, ve onlar�n te�hise ve tedaviye ait kullan�mlar�.

Country Status (27)

Country Link
EP (1) EP0917581B1 (de)
JP (1) JP3681402B2 (de)
KR (1) KR100502879B1 (de)
CN (1) CN1146664C (de)
AR (1) AR008077A1 (de)
AT (1) ATE383429T1 (de)
AU (1) AU722069B2 (de)
BR (1) BR9710605A (de)
CA (1) CA2261562C (de)
CO (1) CO4650184A1 (de)
CZ (1) CZ297634B6 (de)
DE (1) DE69738452T2 (de)
ES (1) ES2300114T3 (de)
ID (1) ID19420A (de)
IL (2) IL128094A0 (de)
MY (1) MY120425A (de)
NO (1) NO323611B1 (de)
NZ (1) NZ333908A (de)
PE (1) PE99498A1 (de)
PL (1) PL189415B1 (de)
PT (1) PT917581E (de)
RU (1) RU2209211C2 (de)
SK (1) SK7799A3 (de)
TR (1) TR199900155T2 (de)
TW (1) TW565571B (de)
WO (1) WO1998004718A1 (de)
ZA (1) ZA976666B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP1056471A4 (de) * 1998-01-29 2001-05-30 Tanox Inc BEHANDLUNG ATOPISCHER DERMATITIS MIT IgE ANTAGONISTEN
CA2330527A1 (en) * 1998-06-15 1999-12-23 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
EP1208194A2 (de) * 1999-08-09 2002-05-29 Genaissance Pharmaceuticals, Inc. Isogene arzneimittel-ziele: polymorphismen des gens der immunglobulin e rezeptor i alpha untereinheit
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
DE10026998A1 (de) * 2000-05-31 2001-12-13 Fresenius Kabi De Gmbh Verfahren zur Herstellung einer kosmetischen Zusammensetzung, die humanes Serum Albumin umfasst, welches aus transgenen nicht-menschlichen Säugern erhalten wurde
UA93662C2 (uk) 2000-12-07 2011-03-10 Эли Лилли Энд Компани Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
DK2401383T3 (da) 2009-02-27 2013-12-16 Novartis Ag Fremgangsmåder til udvælgelse af eukaryote celler, som udtrykker et heterologt protein
WO2012169735A2 (ko) * 2011-06-07 2012-12-13 (주)네오팜 FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물
RU2506271C2 (ru) * 2011-06-22 2014-02-10 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД А2, СЕЛЕКТИВНО СВЯЗЫВАЮЩИЙ HSA, РЕКОМБИНАНТНАЯ ДНК pa2, КОДИРУЮЩАЯ HSA-СВЯЗЫВАЮЩУЮ ЧАСТЬ ПОЛИПЕПТИДА A2, ЕГО ПРОДУЦЕНТ - РЕКОМБИНАНТНЫЙ ШТАММ Escherichia coli M15-A2, СОДЕРЖАЩИЙ РЕКОМБИНАНТНУЮ ПЛАЗМИДНУЮ ДНК pQE 32-pa2, ОБЕСПЕЧИВАЮЩУЮ ПОЛУЧЕНИЕ ПОЛИПЕПТИДА A2 И ПРИМЕНЕНИЕ ПОЛИПЕПТИДА А2 ДЛЯ ДИАГНОСТИКИ МИКРОАЛЬБУМИНУРИИ И ВЫДЕЛЕНИЯ HSA ИЗ СЫВОРОТКИ КРОВИ
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
JP2018515073A (ja) * 2015-05-04 2018-06-14 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ Ｆｃ融合タンパク質のトランスジェニック産生
EP3192806A1 (de) 2016-01-13 2017-07-19 Affiris AG Alpha-kette des hochaffinen ige-rezeptors (fceria)
JP7127859B2 (ja) * 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
BR112022000246A2 (pt) * 2019-07-08 2022-02-22 Gi Innovation Inc Dímero polipeptídico com elevado teor de ácido siálico, compreendendo o domínio extracelular da subunidade alfa do receptor fc de ige e composição farmacêutica compreendendo o mesmo
CN114302891A (zh) * 2019-07-08 2022-04-08 普罗根有限公司 新的il-10变体蛋白及其用途
CN111773392B (zh) * 2020-05-25 2023-04-07 河南省生物工程技术研究中心 一种人血白蛋白/寡核苷酸纳米颗粒及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962035A (en) * 1987-12-01 1990-10-09 President And Fellows Of Harvard College DNA encoding IgE receptor alpha-subunit or fragment thereof
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
CA2059842A1 (en) * 1991-02-11 1992-08-12 Richard A. Chizzonite Ige-receptor-antibodies

Also Published As

Publication number Publication date
JP3681402B2 (ja) 2005-08-10
CZ24699A3 (cs) 1999-04-14
IL128094A0 (en) 1999-11-30
CA2261562C (en) 2011-04-05
AU722069B2 (en) 2000-07-20
PL189415B1 (pl) 2005-08-31
ES2300114T3 (es) 2008-06-01
CN1229439A (zh) 1999-09-22
IL128094A (en) 2006-08-20
NO990328L (no) 1999-02-19
AU4202597A (en) 1998-02-20
EP0917581B1 (de) 2008-01-09
CA2261562A1 (en) 1998-02-05
EP0917581A1 (de) 1999-05-26
DE69738452D1 (de) 2008-02-21
WO1998004718A1 (en) 1998-02-05
ATE383429T1 (de) 2008-01-15
ID19420A (id) 1998-07-09
CO4650184A1 (es) 1998-09-03
KR100502879B1 (ko) 2005-07-25
SK7799A3 (en) 1999-07-12
JP2000516089A (ja) 2000-12-05
NO990328D0 (no) 1999-01-25
MY120425A (en) 2005-10-31
DE69738452T2 (de) 2008-12-24
HK1020352A1 (en) 2000-04-14
KR20000029563A (ko) 2000-05-25
NO323611B1 (no) 2007-06-18
TW565571B (en) 2003-12-11
PE99498A1 (es) 1999-01-21
ZA976666B (en) 1999-01-25
CN1146664C (zh) 2004-04-21
RU2209211C2 (ru) 2003-07-27
AR008077A1 (es) 1999-12-09
PT917581E (pt) 2008-04-11
NZ333908A (en) 1999-10-28
BR9710605A (pt) 1999-08-17
CZ297634B6 (cs) 2007-02-21
PL331356A1 (en) 1999-07-05

Similar Documents

Publication Publication Date Title
TR199900155T2 (xx) Bir IgE ba�lama alan� ve bir HSA bile�eni ihtiva eden f�zyon polipeptidleri, ve onlar�n te�hise ve tedaviye ait kullan�mlar�.
Babinska et al. F11-receptor (F11R/JAM) mediates platelet adhesion to endothelial cells: role in inflammatory thrombosis
DK0602126T3 (da) Immunoglobulinvarianter til specifikke FC epsilon-receptorer
Levine Development of artificial salivas
Ferreira et al. Purification and characterization of recombinant Bet v I, the major birch pollen allergen. Immunological equivalence to natural Bet v I.
Colombo et al. The allergens of Parietaria
Quinti et al. Circulating IgG autoantibodies to IgE in atopic syndromes
ATE269402T1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
Zhang et al. DNA–affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2
EP2083018A3 (de) Zusammensetzungen und Verfahren mit Bezug zu STOP-1
WO2002058728A3 (en) Polypeptides capable of binding to cd64 and comprising one or more heterologous t cell epitopes, and their uses
Gruber et al. IgE rheumatoid factors: quantification in synovial fluid and ability to induce synovial mast cell histamine release
EE05293B1 (et) RG1 polpeptiidiga seonduv antikeha, seda h?lmav immunkonjugaat ja nende kasutamine
Schønheyder et al. Fractionation of Aspergillus fumigatus antigens by hydrophobic interaction chromatography and gel filtration
WO2003054019A3 (en) Therapeutic monoclonal anti-tirc7 antibodies for use in immune related and other diseases
Sridhara et al. Immunocheraical investigation of allergens from Rhizopus nigricans
ATE293456T1 (de) Behandlung und bestimmung von gram-positiven kokkeninfektionen
Ayuso et al. Purification of Par j I, the major allergen of Parietaria judaica pollen
Meyer Dynamics of" conditioning" film formation on biomaterials.
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
Chardin et al. Protein and allergen analysis of latex mattresses
Paliwal et al. Monoclonal, antigen-specific, T cell contrasuppressor factor expresses determinants of TCR alpha-chain (not necessarily TCR beta-chain), having a molecular mass of about 40 kDa.
Stanworth IgE and Reaginic Antibodies: Immunochemistry of IgE
Jaggi et al. Purification and characterization of allergens from Xanthium strumarium pollen
Soter High molecular weight neutrophil chemotactic factor: recognition, characterization, and role in the deactivation of neutrophilic leukocytes